PDF(Pubmed)
Abstract：
Long-term disease control is achieved in 80-90% of patients with acute lymphoblastic leukemia of B origin (B-ALL). About half of adult and 10% of pediatric patients develop refractory or relapsed disease, whereas survival after relapse accounts about 10% in adults and 30-50% in children. Allogeneic bone marrow transplantation offers remarkable benefit in cases with unfavorable outcome. Nevertheless, novel immunotherapeutic options have been approved for patients with adverse prognosis. Immunotherapeutic agents, nowadays, are preferred over standard chemotherapy for patients with relapsed or refractory B-ALL The mode of action, efficacy and safety data of immunotherapeutic agents released, indications and sequence of those therapies over the course of treatment, are herein reviewed.
摘要：
在80-90％的B起源的急性淋巴细胞白血病（B-ALL）患者中实现了长期疾病控制。大约一半的成年人和10％的儿科患者发展为难治性或复发性疾病，而复发后的生存率在成人中约占10％，在儿童中约占30-50％。同种异体骨髓移植在预后不良的病例中具有显着的益处。然而，新的免疫治疗方案已被批准用于预后不良的患者.免疫治疗剂，如今,对于复发或难治性B-ALL患者，优于标准化疗。已发布的免疫治疗剂的疗效和安全性数据，在治疗过程中这些疗法的适应症和顺序，在此审查。
